神经科学生物制药公司利用实验性干细胞疗法治疗了第四名患有严重克罗恩病的病人,显示了早期的安全和前景。 NeuroScientific Biopharmaceuticals treated a fourth patient with severe Crohn’s using its experimental stem cell therapy, showing early safety and promise.

通过实验性"StemSmart"干细胞治疗,即通过输入输入的,来自捐赠者的骨髓的现成治疗,NeuroScientific Biopharmaceuticals已经治疗了第四名患有状克罗恩病的患者. NeuroScientific Biopharmaceuticals has treated a fourth patient with fistulising Crohn’s disease using its experimental “StemSmart” stem cell therapy, an off-the-shelf treatment derived from donor bone marrow and administered via IV. 在澳大利亚特殊治疗计划下批准的治疗方法, 现正在标准治疗失败的患者中进行测试。 The therapy, approved under Australia’s special access scheme, is being tested in patients who’ve failed standard treatments. 早期结果表明安全和可能的临床改进是安全的,初步组群的数据为2026年开始的计划中的第二阶段试验提供了信息。 Early results suggest safety and potential clinical improvement, with data from the initial cohort informing a planned phase two trial starting in 2026. 该公司还正在开发基于蛋白质的治疗EntinB,并探索移植排斥和炎症方面的更广泛应用。 The company is also developing EmtinB, a protein-based therapy, and exploring broader applications in transplant rejection and inflammation. 预计2026年1月将取得第一批临床结果。 First clinical results are expected in January 2026.